Month: June 2026

Introduction and Objective: The health and psychosocial impacts of recurrent severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia (IAH) in adults with type 1 diabetes (T1D) who use continuous glucose monitors (CGM) and insulin pumps remain poorly understood. This study describes the health and psychosocial burden of adults with T1D using CGM and insulin […]

Introduction and Objective: Insulin pump-based Automated Insulin Delivery (AID) therapy has significantly improved glucose control and reduced hypoglycemic risk in patients with Type 1 Diabetes (T1D), but is currently only approved to use with U-100 insulin, which can be problematic in patients with severe insulin resistance, due to frequent cartridge volume exhaustion, infusion site saturation, […]

Introduction and Objective: Although worsening glycemic control during the menstrual cycle (MC) has been reported in type 1 diabetes (T1D), the influence of premenstrual syndrome (PMS) remains poorly defined. Objectives: i) To characterize PMS severity across MC phases; ii) To evaluate associations between PMS severity and glycemic control, (iii) To assess whether higher PMS severity […]

Introduction and Objective: This post hoc analysis assessed efficacy and hypoglycemia outcomes of IcoSema (a once-weekly combination of insulin icodec + semaglutide) vs comparators (COMBINE 1 [C1]: icodec; COMBINE 2 [C2]: semaglutide 1.0 mg; COMBINE 3 [C3]: basal-bolus therapy) in insulin-experienced (C1+3) or GLP-1 RA experienced (C2) adults with T2D by baseline BMI subgroups.Methods: Treatment […]

Introduction and Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated superior glycemic and weight-loss efficacy in randomized trials. However, real-world evidence in South Asian populations remains limited. This study was done to evaluate the early real-world effectiveness and safety of tirzepatide in Indian adults with type 2 […]

Introduction and Objective: Type 1 diabetes (T1D) is an autoimmune disorder marked by islet autoantibodies. First-degree relatives (FDRs) of individuals with T1D have a 10-15-fold higher risk of developing T1D than the general population. Screening for four autoantibodies—glutamic acid decarboxylase (anti-GAD), protein tyrosine phosphatase (anti-IA2), insulin (IAA), and Zinc Transporter 8 (anti-ZnT8)—enables early detection of […]

Introduction and Objective: The literature reports that Mexican American children are at risk for diabetes, hypertension, renal dysfunction, cardiovascular and gallbladder disease, risk increases if the child has overweight or obesity. In 2005 we found that by the age of three 25% of boys and 15% of girls were either overweight or obese, but the […]

Introduction and Objective: Faricimab, the only bispecific antibody targeting both Ang-2 and VEGF-A, is a novel treatment for diabetic macular edema (DME). Real-world evidence is lacking on the impact of baseline diabetes severity on its long-term clinical/economic outcomes.Methods: This retrospective cohort study linked a DME cohort from a large national payer (administrative claims) with the […]

Introduction and Objective: Implementing lifestyle interventions guided by continuous glucose monitor (CGM) data can potentially prevent progression and reduce risk of prediabetes and type 2 diabetes (T2D). Maintaining healthy behaviors is particularly difficult in high-stress work environments like health care workers (HCWs). Sutter Health created a Metabolic Wellness Program (MWP) to educate on interpreting CGM […]